Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 03 Aug 2026
Revised 05 Sep 2026
Accepted 25 Sep 2026

Natural Resources for Human Health 2026, Vol. 6 (23s): 1350-1356

KEYWORDS:
Pharmaceutical Manufacturing, Hospital Compounding, Compounding Equipment, Technological Innovations, SFDA Regulatory Compliance, MOH Standards

Pharmaceutical Manufacturing and Hospital Compounding Equipment: Technological Innovations and SFDA/MOH Regulatory Compliance

Azmi Eid Alsubhi[1], Mohammed Abdullah Allehyani[2], Reham Ahmed Alemam[3], Khaled Ali Babalgeth[4], Shatha Mohammed Rmbo[5], Hifaa Abdullah Alotaibi[6], Hussam Saud Alharbi[7], Naif Otaiwy Allehyani[8], Ibrahim Mohammed Ali[9], Bayan Ahmed Bakhsh[10], Muhammad Mustafa Imam[11], Mosleh Mohammed Alzaidi[12]

[1,2,3,4,5,6,7,8,9,10,11,12,13]Doctor of Pharmacy & Pharmacists & Pharmacy technicians MOH, Hera General hospital KSA
Email: [1] alsubhiazmi@yahoo.com , [2] ralemam@MOH.com.sa , [3] Kbabalgeth@moh.gov.sa , [4] mohamed.a.allehyani@hotmail.com , [5] halharbi92@moh.gov.sa , [6] noallahyani@MOH.com.sa , [7] halotaibi33@moh.gov, [8] sammemam@moh.com , [9] sasrambo@moh.gov.sa , [10] bayanbakhsh@outlook.com, [11] Ibraaahim707@hotmail.com, [12] masleh-m@hotmail.com

ABSTRACT: The global pharmaceutical manufacturing sector relies heavily on high-precision machinery and advanced cyber-physical systems to ensure therapeutic efficacy, patient safety, and strict regulatory compliance. Unlike conventional industrial sectors, pharmaceutical production requires sub-millimeter mechanical tolerances, validated aseptic processing environments, and real-time quality verification. This review paper presents a systematic classification of modern pharmaceutical manufacturing equipment across oral solid, liquid, semi-solid, sterile parenteral, and biopharmaceutical dosage forms. Furthermore, it critically examines contemporary technological innovations—including Continuous Manufacturing (CM), Process Analytical Technology (PAT), and Pharma 4.0 autonomous control—and evaluates how precision engineering, specialized metallurgy, and lifecycle qualification protocols minimize batch-to-batch variability while upholding current Good Manufacturing Practice (cGMP) standards. Finally, this review highlights the pivotal regulatory and operational roles of Saudi Food and Drug Authority (SFDA) inspectors, Ministry of Health (MOH) Compliance Directorate auditors, and hospital pharmacy personnel in auditing equipment classification, validating automated intravenous (IV) compounding and unit-dose packaging technologies, and ensuring end-to-end medication quality and patient safety.

1. INTRODUCTION

Pharmaceutical manufacturing has undergone a profound technological transformation over the past two decades, evolving from traditional, labor-intensive batch processing to highly automated, precision-driven operations. The clinical efficacy and safety profile of any medicinal product depend directly on the mechanical accuracy, thermodynamic stability, and environmental control of the machinery utilized during synthesis, formulation, filling, and primary packaging. Even minor deviations in mechanical tolerances, shear stress, thermal gradients, pressure differentials, or powder mixing homogeneity can alter the

polymorphic form of an Active Pharmaceutical Ingredient (API), compromise dissolution kinetics and bioavailability, or introduce microbial and particulate contamination (ICH, 2009; WHO, 2014).

In response to stringent international regulatory frameworks enforced by global and national health authorities—including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Saudi Food and Drug Authority (SFDA), the Saudi Ministry of Health (MOH), and the World Health Organization (WHO)—equipment engineering has shifted toward Quality by Design (QbD) principles (ICH, 2008; ICH, 2009). Modern pharmaceutical machinery integrates advanced metrology, non-destructive inline sensors, and closed-loop feedback systems directly into both industrial production lines and hospital cleanroom compounding suites (FDA, 2004; ASHP, 2022). This article provides a comprehensive technical review of the structural classifications of pharmaceutical machinery, the integration of smart digital technologies, and the precision engineering parameters governing contemporary drug production. Furthermore, it contextualizes these engineering standards within national healthcare governance by examining the integrated roles of SFDA inspectors, MOH Compliance Directorate auditors, and hospital pharmacy personnel in auditing equipment qualification, validating emerging clinical compounding technologies, and enforcing Good Manufacturing Practice (GMP) and Good Compounding Practice (GCP) compliance (MOH, 2023; SFDA, 2024a).

2. COMPREHENSIVE CLASSIFICATION OF PHARMACEUTICAL MANUFACTURING EQUIPMENT

Pharmaceutical manufacturing equipment is systematically classified according to the physicochemical nature of the Active Pharmaceutical Ingredient (API), the intended route of administration, sterility requirements, and the level of direct product impact under current Good Manufacturing Practice (cGMP) frameworks (WHO, 2014; SFDA, 2024a). From a regulatory and engineering standpoint, factory machinery and hospital compounding systems are categorized into six primary operational classes:

2.1 Oral Solid Dosage (OSD) Processing Equipment

Oral solid dosage forms—comprising tablets, hard-shell capsules, and granules—represent the largest segment of pharmaceutical manufacturing and require high-precision mechanical handling of powders (Lee et al., 2015):

Size Reduction and Milling Machines: High-shear hammer mills, conical screen mills (Comils), and fluid-energy jet mills engineered to achieve micronized particle size distributions that directly govern API dissolution rates and bioavailability.

Powder Blending and Homogenization Systems: Diffusion blenders (V-blenders, double-cone blenders, and bin/tote blenders) and convective high-shear mixers designed to eliminate dead zones and ensure content uniformity for low-dose potent drugs.

Granulation and Drying Equipment: High-shear wet granulators, roller compactors (for dry granulation of moisture-sensitive APIs), and fluidized-bed processors that integrate spraying, granulation, and thermodynamic drying within a single closed-loop chamber.

Tablet Compression and Encapsulation Machinery: High-speed rotary tablet presses equipped with servo-driven compression rollers, force-feeder paddles, and real-time weight-control feedback sensors, alongside automated dosator and tamping-pin capsule filling machines.

Film and Sugar Coating Systems: Perforated pan coaters utilizing precision atomizing spray guns, automated air-handling units, and infrared temperature sensors to apply functional, enteric, or aesthetic polymer films.

2.2 Liquid and Semi-Solid Dosage Form Equipment

The manufacture of syrups, suspensions, emulsions, creams, ointments, and transdermal gels requires specialized fluid dynamics and thermal transfer precision to prevent phase separation or aeration:

Jacketed Mixing Vessels and Agitators: Electropolished 316L stainless steel vessels fitted with variable-speed turbine impellers, anchor agitators, and automated heating/cooling jackets for precise viscosity and temperature control.

High-Shear Homogenizers and Colloid Mills: Rotor-stator homogenizers and high-pressure microfluidizers engineered to generate sub-micron droplet sizes in sterile emulsions and topical creams, ensuring long-term physical stability.

Vacuum Emulsifying Mixers: Closed-system planetary mixers operating under vacuum to eliminate air entrapment and oxidation during the compounding of viscous ointments and dermatological gels.

2.3 Sterile Parenteral and Aseptic Processing Equipment

Parenteral products (injectables, ophthalmics, and biologics) pose the highest clinical risk to patients and must be manufactured under strict aseptic conditions compliant with EU GMP Annex 1 and ISO 14644-1 cleanroom classifications (EMA, 2022; ISO, 2015):

Depyrogenation and Sterilization Units: Saturated steam autoclaves (utilizing vacuum-assisted air removal), dry-heat depyrogenation tunnels (operating at 250°C–300°C to destroy bacterial endotoxins on glass vials), and ethylene oxide (EtO) or vaporized hydrogen peroxide (VHP) sterilizers.

Aseptic Liquid Filling and Stoppering Lines: High-precision peristaltic, rotary piston, and time-pressure filling needles housed inside Restricted Access Barrier Systems (RABS) or fully enclosed aseptic isolators to eliminate human operator intervention.

Lyophilization (Freeze-Drying) Systems: Industrial vacuum freeze-dryers equipped with temperature-controlled shelves, condenser coils, and automated vial-loading systems designed to preserve thermolabile biologics, vaccines, and peptides.

Hospital Sterile Compounding Engineering Controls: Miniature aseptic equipment audited by MOH Compliance Directorate inspectors and operated by hospital pharmacists, including ISO Class 5 Laminar Airflow Workstations (LAFWs), Biological Safety Cabinets (BSCs), and automated gravimetric Total Parenteral Nutrition (TPN) compounders (USP, 2020; USP, 2023; MOH, 2023).

2.4 Biopharmaceutical and Upstream/Downstream Processing Equipment

The rapid growth of monoclonal antibodies, recombinant proteins, and gene therapies has necessitated specialized bioprocessing machinery:

Bioreactors and Fermenters: Stainless steel and single-use disposable bioreactors fitted with precision dissolved oxygen (DO), pH, and foam sensors, alongside sparging systems for mammalian cell culture or microbial fermentation.

Downstream Purification Skids: Tangential Flow Filtration (TFF) units, continuous centrifuges, and automated preparative chromatography columns engineered to isolate and purify target biomolecules with high yield and viral clearance.

2.5 Primary and Secondary Packaging Machinery

Packaging equipment serves as the final barrier protecting the drug product from moisture, oxygen, light, and tampering:

Primary Packaging Lines: Thermoforming and cold-forming blister packaging machines (utilizing Alu-Alu or PVC/PVDC films), automated bottle-filling and desiccant-inserting lines, and induction cap-sealing units.

Secondary Packaging and Serialization Systems: High-speed cartoners, bundle wrappers, and inline vision-inspection cameras integrated with Track-and-Trace serialization printers (such as the SFDA Drug Track and Trace System, RSD) to prevent counterfeiting and facilitate recalls (SFDA, 2024b).

Hospital Unit-Dose Automation: Automated oral solid packaging robots and Automated Dispensing Cabinets (ADCs) utilized within hospital pharmacies to ensure barcode-verified, patient-specific medication distribution (ASHP, 2022).

2.6 Critical Pharmaceutical Utilities and Support Systems

Under cGMP inspection frameworks (PIC/S, 2023), auxiliary utility systems that directly contact the product or control the manufacturing environment are classified as critical direct-impact systems:

Pharmaceutical Water Generation and Distribution: Multi-effect distillation units, reverse osmosis (RO) skids, and continuous electrodeionization (CEDI) loops producing Purified Water (PW) and Water for Injection (WFI) maintained at ≥80°C to inhibit biofilm formation.

Heating, Ventilation, and Air Conditioning (HVAC) Systems: Dedicated air-handling units equipped with High-Efficiency Particulate Air (HEPA H13/H14) filters, differential pressure monitors, and relative humidity controllers maintaining cascading pressure gradients across cleanroom zones (ISO, 2015).

Automated Cleaning and Sterilization Loops: Integrated Clean-in-Place (CIP) and Sterilize-in-Place (SIP) skids utilizing conductivity sensors and spray-ball coverage validation to prevent cross-contamination in multi-product facilities (EMA, 2015).

Table 1. Summary of Pharmaceutical Equipment Classifications, Engineering Parameters, and Regulatory Focus.

Equipment Category	Key Machinery Examples	Critical Engineering Parameters	Primary Regulatory & Compliance Focus
Oral Solid Dosage (OSD)	Rotary tablet presses, fluid-bed dryers, high-shear mixers	Compression force (kN), airflow velocity, moisture content	Content uniformity, dissolution kinetics, cross-contamination prevention (ICH Q8)
Liquid & Semi-Solid	Jacketed vessels, rotor-stator homogenizers, vacuum mixers	Shear rate (rpm), thermal uniformity, vacuum pressure	Viscosity stability, phase homogeneity, microbial bioburden control
Sterile Parenteral	Aseptic isolators, lyophilizers, TPN compounders	ISO Class 5 airflow, HEPA integrity, shelf temperature	Sterility assurance, endotoxin removal, aseptic technique (EU Annex 1, USP <797>)
Biopharmaceutical	Single-use bioreactors, TFF skids, chromatography columns	Dissolved oxygen, pH stability, transmembrane pressure	Viral clearance, biomolecule integrity, extractables/leachables testing
Packaging & Serialization	Blister lines, vision cameras, hospital unit-dose robots	Sealing temperature, optical rejection accuracy	Tamper evidence, serialization data integrity, barcode verification (SFDA RSD)
Critical Utilities	WFI loops, HVAC systems, CIP/SIP skids	Loop temperature (≥80°C), pressure differentials (Pa), conductivity	Biofilm prevention, cleanroom air classification, cleaning validation (PIC/S GMP)

3. TECHNOLOGICAL INNOVATIONS AND PRECISION ENGINEERING

Modern pharmaceutical equipment has transitioned from isolated, manually controlled mechanical units to integrated cyber-physical systems governed by Industry 4.0 and Quality by Design (QbD) architectures (ICH, 2009; Lee et al., 2015):

Continuous Manufacturing (CM): Unlike traditional batch processing—where materials are tested offline between discrete steps—CM integrates feeding, blending, granulation, compression, and coating into an uninterrupted, closed-loop production line. Guided by ICH Q13 standards, CM reduces facility footprints, accelerates scale-up, and minimizes material waste (Burcham et al., 2018; ICH, 2022).

Process Analytical Technology (PAT): PAT embeds non-destructive, real-time spectroscopic sensors—such as Near-Infrared (NIR), Raman spectroscopy, and laser diffraction—directly into processing streams. These sensors continuously monitor Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs), enabling automated feedback adjustments and Real-Time Release Testing (RTRT) (FDA, 2004).

Precision Engineering and Specialized Metallurgy: To withstand aggressive chemical cleaning agents and prevent metallic leaching, product-contact surfaces are fabricated from low-carbon austenitic stainless steel (AISI 316L) electropolished to a surface roughness (Ra) below 0.4 μm. Servo-driven actuators, magnetic levitation pumps, and sub-millimeter machining

tolerances ensure reproducible dosing accuracy in both industrial filling lines and automated hospital compounders (EMA, 2022).

Lifecycle Qualification and Risk Management: Under Quality Risk Management (ICH Q9) principles, every piece of equipment undergoes rigorous four-stage qualification—Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ)—supported by Computerized System Validation (CSV) to ensure electronic data integrity (ICH, 2023; PIC/S, 2023).

4. REGULATORY AND CLINICAL OVERSIGHT: SFDA INSPECTORS, MOH COMPLIANCE DIRECTORATE, AND HOSPITAL PHARMACISTS

In the Kingdom of Saudi Arabia, ensuring medication safety requires a seamless continuum of oversight spanning industrial drug factories and hospital pharmacy preparation units. Understanding the classification, precision engineering, and technological innovations of pharmaceutical equipment is essential not only for regulatory inspectors at the Saudi Food and Drug Authority (SFDA), but also for regulatory auditors within the Ministry of Health (MOH) Compliance Directorate and clinical staff in MOH hospitals.

4.1 SFDA Pharmacist Inspectors: Industrial Manufacturing Oversight

Pharmacists serving as GMP inspectors at the SFDA play a critical frontline role in evaluating, classifying, and auditing large-scale manufacturing equipment within drug factories. Utilizing a risk-based approach aligned with ICH Q9, SFDA inspectors examine critical processing units (such as tablet presses, fluid-bed dryers, and sterile filling lines) to verify that material construction (e.g., 316L stainless steel), precision tolerances, and lifecycle qualification stages (DQ, IQ, OQ, and PQ) prevent cross-contamination and batch variability (ICH, 2023; SFDA, 2024a). In accordance with SFDA GMP guidelines, inspectors also conduct Computerized System Validation (CSV) audits on Pharma 4.0 technologies—including Continuous Manufacturing (CM) and Process Analytical Technology (PAT)—to guarantee strict data integrity, electronic signature compliance, and audit trail security (SFDA, 2024a).

4.2 MOH Compliance Directorate Auditors: Healthcare Facility Governance and Inspection

Within the healthcare delivery sector, regulatory auditors and inspectors at the MOH Compliance Directorate enforce stringent statutory and technical standards across governmental and private healthcare institutions. A deep understanding of pharmaceutical equipment classification enables MOH Compliance Directorate personnel to conduct thorough facility licensing inspections, environmental audits, and compliance surveillance of hospital pharmacies and sterile compounding centers. Compliance auditors verify that healthcare facilities maintain valid operational permits for specialized compounding machinery, adhere strictly to preventive maintenance and metrological calibration schedules, and enforce validated cleanroom engineering controls (such as ISO Class 5/7 air quality, HEPA filtration integrity, and room pressure differentials) in alignment with national regulations and USP <797>/<800> standards (ISO, 2015; USP, 2020; USP, 2023; MOH, 2023).

4.3 Hospital Pharmacists and Pharmacy Technicians: Precision Compounding and Automation

Inside MOH hospitals, clinical pharmacists, compounding pharmacists, and pharmacy technicians directly operate miniature, precision-engineered counterparts of industrial pharmaceutical machinery—particularly within sterile Intravenous (IV) admixture suites, Total Parenteral Nutrition (TPN) units, oncology cytotoxic preparation rooms, and central inpatient pharmacies (ASHP, 2022). Mastery of equipment engineering and classification empowers hospital pharmacy personnel to safely operate, calibrate, and validate:

Primary Engineering Controls (PECs): Including Laminar Airflow Workstations (LAFWs), Biological Safety Cabinets (BSCs), and Compounding Aseptic Containment Isolators (CACIs) that rely on precision airflow dynamics to maintain sterility and protect operators from hazardous drugs (USP, 2020; USP, 2023).

Automated IV and TPN Compounders: Gravimetric and volumetric peristaltic pumping systems equipped with barcode verification and inline sensors that require sub-milliliter dosing precision to prevent fatal electrolyte or chemotherapy dosing errors (ASHP, 2022).

Robotic Unit-Dose Packaging and Automated Dispensing Systems: High-speed oral solid packaging machines that utilize precision heat-sealing mechanisms and optical inspection sensors to ensure tamper-evident, accurately labeled patient doses (MOH, 2023).

By applying cGMP-aligned protocols—such as daily gravimetric accuracy checks, automated Clean-in-Place (CIP) or aseptic sanitization validation, and electronic batch record logging—hospital pharmacy personnel translate industrial engineering rigor into direct patient safety at the point of care.

5. CONCLUSION

The convergence of specialized pharmaceutical machinery, smart cyber-physical technologies, and ultra-high precision engineering forms the cornerstone of modern medicine production. Innovations in Process Analytical Technology, continuous processing architectures, servo-driven mechanics, and aseptic isolator automation have substantially minimized human intervention and batch-to-batch variability. By strictly adhering to metallurgical standards, sub-millimeter tolerances, and international cGMP qualification frameworks, contemporary pharmaceutical manufacturing equipment ensures that critical therapies are produced with optimal efficiency, reproducibility, and patient safety. Ultimately, aligning these advanced engineering standards with coordinated regulatory and operational oversight—by SFDA inspectors in factories, MOH Compliance Directorate auditors across healthcare facilities, and hospital pharmacists in clinical compounding and automation units—ensures an unbroken chain of pharmaceutical quality and patient safety across the Kingdom.

REFERENCES

[1] American Society of Health-System Pharmacists (ASHP). (2022). ASHP guidelines on compounding sterile preparations. American Journal of Health-System Pharmacy, 79(15), 1275–1306.

[2] Burcham, C. L., Florence, A. J., & Johnson, M. D. (2018). Continuous manufacturing in pharmaceutical process development and manufacturing. Annual Review of Chemical and Biomolecular Engineering, 9, 253–281.

[3] European Medicines Agency (EMA). (2015). Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities(EMA/CHMP/CVMP/SWP/169430/2012). EMA.

[4] European Medicines Agency (EMA). (2022). EudraLex – Volume 4: Good Manufacturing Practice (GMP) guidelines – Annex 1: Manufacture of sterile medicinal products. European Commission.

[5] International Council for Harmonisation (ICH). (2008). ICH harmonised tripartite guideline: Pharmaceutical quality system Q10. ICH. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf

[6] International Council for Harmonisation (ICH). (2009). ICH harmonised tripartite guideline: Pharmaceutical development Q8(R2). ICH. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf

[7] International Council for Harmonisation (ICH). (2022). ICH harmonised guideline: Continuous manufacturing of drug substances and drug products Q13. ICH.

[8] International Council for Harmonisation (ICH). (2023). ICH harmonised guideline: Quality risk management Q9(R1). ICH.

[9] International Organization for Standardization (ISO). (2015). Cleanrooms and associated controlled environments — Part 1: Classification of air cleanliness by particle concentration (ISO Standard No. 14644-1:2015). ISO.

[10] Lee, S. L., O'Connor, T. F., Yang, X., Cruz, C. N., Chatterjee, S., Madurawe, R. D., Moore, C. M. V., Yu, L. X., & Woodcock, J. (2015). Modernizing pharmaceutical manufacturing: From batch to continuous production. Journal of Pharmaceutical Innovation, 10(3), 191–199.

[11] Ministry of Health (MOH). (2023). Guidelines for pharmaceutical care and sterile compounding standards in healthcare facilities. General Directorate of Pharmaceutical Care, Kingdom of Saudi Arabia.

[12] Pharmaceutical Inspection Co-operation Scheme (PIC/S). (2023). Guide to Good Manufacturing Practice for medicinal products(PE 009-17). PIC/S Secretariat.

[13] Saudi Food and Drug Authority (SFDA). (2024a). Guide to Good Manufacturing Practice for medicinal products (Version 4.2). Riyadh, Kingdom of Saudi Arabia: SFDA. https://www.sfda.gov.sa/en/guide/69378

[14] Saudi Food and Drug Authority (SFDA). (2024b). SFDA products classification guidance (Version 8.0). Riyadh, Kingdom of Saudi Arabia: SFDA. https://www.sfda.gov.sa/sites/default/files/2024-11/classification%20guidance%208.0%20.pdf.pdf

[15] United States Pharmacopeial Convention (USP). (2020). USP general chapter <800>: Hazardous drugs—Handling in healthcare settings. In USP-NF. United States Pharmacopeia.

[16] United States Pharmacopeial Convention (USP). (2023). USP general chapter <797>: Pharmaceutical compounding—Sterile preparations. In USP-NF. United States Pharmacopeia.

[17] U.S. Food and Drug Administration (FDA). (2004). Guidance for industry: PAT — A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Center for Drug Evaluation and Research (CDER). https://www.fda.gov/media/71012/download

[18] World Health Organization (WHO). (2014). WHO good manufacturing practices for pharmaceutical products: Main principles (WHO Technical Report Series, No. 986, Annex 2). WHO Press.